专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009068689A3 COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS 审中-公开
标题翻译：蛋白酪氨酸磷酸化酶抑制剂和人类生长激素的组合用于治疗肌肉病和相关疾病
公开(公告)号：WO2009068689A3
公开(公告)日：2009-08-06
申请号：PCT/EP2008066554
申请日：2008-12-01
申请人： NOVARTIS AG , BARNES DAVID , PAUL ANGELIKA CHRISTINA
发明人： BARNES DAVID , PAUL ANGELIKA CHRISTINA
IPC分类号： A61K38/27 , A61K31/433 , A61P21/00
CPC分类号： A61K38/27 , A61K31/433
摘要： The invention relates to the use of a combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of musculoskeletal diseases, particularly for the treatment of muscle atrophy.
摘要翻译：本发明涉及蛋白酪氨酸磷酸酶抑制剂和人生长激素的组合用于治疗肌肉骨骼疾病，特别是用于治疗肌肉萎缩的用途。

2. 发明申请

WO2007115058A2 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2007115058A2
公开(公告)日：2007-10-11
申请号：PCT/US2007065421
申请日：2007-03-29
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , NEUBERT ALAN , BARNES DAVID , KWAK YOUNG-SHIN , NAKAJIMA KATSUMASA , BEBERNITZ GREGORY RAYMOND , COPPOLA GARY MARK , KIRMAN LOUISE , SERRANO-WU MICHAEL H , STAMS TRAVIS , TOPIOL SIDNEY WOLF , VEDANANDA THALATHTHANI RALALAG , WAREING JAMES RICHARD
发明人： NEUBERT ALAN , BARNES DAVID , KWAK YOUNG-SHIN , NAKAJIMA KATSUMASA , BEBERNITZ GREGORY RAYMOND , COPPOLA GARY MARK , KIRMAN LOUISE , SERRANO-WU MICHAEL H , STAMS TRAVIS , TOPIOL SIDNEY WOLF , VEDANANDA THALATHTHANI RALALAG , WAREING JAMES RICHARD
IPC分类号： C07D417/10 , A61K31/433 , A61P3/10 , C07D285/10
CPC分类号： C07D285/10 , C07D417/10
摘要： Compounds of the formula (I) are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.
摘要翻译：式（I）的化合物是蛋白酪氨酸磷酸酶（PTPases）的抑制剂，因此可用于治疗由PTPase活性介导的病症。本发明的化合物也可以用作以磷酸酪氨酸结合区如SH2结构域为特征的其它酶的抑制剂。因此，式（I）化合物可用于预防和/或治疗与大，小血管的肥胖，葡萄糖不耐受，糖尿病，高血压和缺血性疾病相关的胰岛素抵抗，伴随2型糖尿病的病症，包括高脂血症，高甘油三酯血症，动脉粥样硬化，血管再狭窄，肠易激综合征，胰腺炎，脂肪细胞肿瘤和诸如脂肪肉瘤，血脂异常和其它指示胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症，骨质疏松症，肌肉骨骼，神经变性和感染性疾病以及涉及炎症和免疫系统的疾病。

3. 发明申请

WO2007067615A2 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2007067615A2
公开(公告)日：2007-06-14
申请号：PCT/US2006046545
申请日：2006-12-06
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BARNES DAVID , BEBERNITZ GREGORY RAYMOND , COPPOLA GARY MARK , NAKAJIMA KATSUMASA , STAMS TRAVIS , TOPIOL SIDNEY WOLF , VEDANANDA THALATHTHANI RALALAG , WAREING JAMES RICHARD
发明人： BARNES DAVID , BEBERNITZ GREGORY RAYMOND , COPPOLA GARY MARK , NAKAJIMA KATSUMASA , STAMS TRAVIS , TOPIOL SIDNEY WOLF , VEDANANDA THALATHTHANI RALALAG , WAREING JAMES RICHARD
IPC分类号： C07D285/10 , A61K31/433 , C07D417/04 , C07D417/10
CPC分类号： C07D285/10 , C07D417/04 , C07D417/10
摘要： Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer (such as prostate or breast cancer), osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.
摘要翻译：式的化合物是蛋白酪氨酸磷酸酶（PTPases）的抑制剂，因此可用于治疗由PTPase活性介导的病症。本发明的化合物也可以用作以磷酸酪氨酸结合区如SH2结构域为特征的其它酶的抑制剂。因此，式（I）化合物可用于预防和/或治疗与大，小血管的肥胖，葡萄糖不耐受，糖尿病，高血压和缺血性疾病相关的胰岛素抵抗，伴随2型糖尿病的病症，包括高脂血症，高甘油三酯血症，动脉粥样硬化，血管再狭窄，肠易激综合征，胰腺炎，脂肪细胞肿瘤和诸如脂肪肉瘤，血脂异常和其它指示胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症（例如前列腺或乳腺癌），骨质疏松症，神经变性和感染性疾病以及涉及炎症和免疫系统的疾病。

4. 发明申请

WO2012010663A1 2,3,5-TRISUBSTITUTED THIOPHENE COMPOUNDS AND USES THEREOF 审中-公开
标题翻译： 2,3,5-取代的噻吩化合物及其用途
公开(公告)号：WO2012010663A1
公开(公告)日：2012-01-26
申请号：PCT/EP2011062545
申请日：2011-07-21
申请人： NOVARTIS AG , BARNES DAVID , COHEN SCOTT LOUIS , FU JIPING , SHU LEI , ZHENG RUI
发明人： BARNES DAVID , COHEN SCOTT LOUIS , FU JIPING , SHU LEI , ZHENG RUI
IPC分类号： C07D409/04 , A61K31/381 , A61P31/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D498/04
CPC分类号： A61K31/541 , A61K31/381 , A61K31/4025 , A61K31/422 , A61K31/4535 , A61K31/496 , A61K31/4985 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/553 , A61K45/06 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D498/04
摘要： The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要翻译：本发明提供式（I）化合物，其用于制备本发明化合物的方法及其治疗用途。本发明还提供药理活性剂和药物组合物的组合。

5. 发明授权

EP2560976B9 FUROPYRIDINE COMPOUNDS AND USES THEREOF 有权
标题翻译： FUROPYRIDIN-VERBINDIUNGEN和IHRE VERWENDUNG
公开(公告)号：EP2560976B9
公开(公告)日：2017-06-07
申请号：EP11715244
申请日：2011-04-20
申请人： NOVARTIS AG
发明人： BARNES DAVID , CHOPRA RAJIV , COHEN SCOTT LOUIS , FU JIPING , KATO MITSUNORI , LU PEICHAO , SEEPERSAUD MOHINDRA , ZHANG WEI
IPC分类号： C07D491/048 , A61K31/4355 , A61K31/541 , A61P31/14 , A61P35/00 , C07D491/147
CPC分类号： C07D491/147 , C07D491/048

6. 发明专利

CO6680616A2 Compuestos de tiofeno 2.3.5- trisustituidos y usos de los mismos 未知
公开(公告)号：CO6680616A2
公开(公告)日：2013-05-31
申请号：CO13011468
申请日：2013-01-22
申请人： NOVARTIS AG
发明人： BARNES DAVID , COHEN SCOTT LOUIS , FU JIPING , SHU LEI , RUI ZHENG
IPC分类号： C07D409/04 , A61K31/381 , A61P31/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D487/04 , C07D498/04
摘要： La presente invención proporciona un compuesto de la fórmula I:un método para la fabricación de los compuestos de la invención, y sus usos terapéuticos. La presente invención proporciona adicionalmente una combinación de agentes farmacológicamente activos y una composición farmacéutica.

7. 发明专利

SG187561A1 2,3,5-TRISUBSTITUTED THIOPHENE COMPOUNDS AND USES THEREOF 未知
公开(公告)号：SG187561A1
公开(公告)日：2013-03-28
申请号：SG2013004148
申请日：2011-07-21
申请人： NOVARTIS AG
发明人： BARNES DAVID , COHEN SCOTT LOUIS , FU JIPING , SHU LEI , ZHENG RUI
摘要： The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

8. 发明专利

BRPI0710182A2 未知
公开(公告)号：BRPI0710182A2
公开(公告)日：2012-08-07
申请号：BRPI0710182
申请日：2007-03-29
申请人： NOVARTIS AG
发明人： NEUBERT ALAN , BARNES DAVID , KWAK YOUNG-SHIN , NAKAJIMA KATSUMASA , BEBERNITZ GREGORY RAYMOND , COPPOLA GARY MARK , KIRMAN LOUISE , SERRANO-WU MICHAEL H , STAMS TRAVIS , TOPIOL SIDNEY WOLF , VEDANANDA THALATHTHANI RALALAGE , WAREING JAMES RICHARD
IPC分类号： C07D285/10 , A61K31/433 , A61P3/10 , C07D417/10
摘要： Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

9. 发明专利

PT1963292E DERIVADOS DE TIADIAZOLE COMO AGENTES ANTIDIABÉTICOS 未知
公开(公告)号：PT1963292E
公开(公告)日：2012-05-10
申请号：PT06839094
申请日：2006-12-06
申请人： NOVARTIS AG
发明人： COPPOLA GARY MARK , BEBERNITZ GREGORY RAYMOND , TOPIOL SIDNEY WOLF , BARNES DAVID , NAKAJIMA KATSUMASA , STAMS TRAVIS , ANDA THALATHTHANI RALALAGE , WAREING JAMES RICHARD
IPC分类号： C07D285/10 , A61K31/433 , C07D417/04 , C07D417/10

10. 发明专利

BRPI0619567A2 未知
公开(公告)号：BRPI0619567A2
公开(公告)日：2011-10-04
申请号：BRPI0619567
申请日：2006-12-06
申请人： NOVARTIS AG
发明人： BARNES DAVID , COPPOLA GARY MARK , STAMS TRAVIS , TOPIOL SIDNEY WOLF
IPC分类号： C07D285/10 , A61K31/433 , A61P3/10 , C07D417/10
摘要： Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式